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Clinical Immunology 
Summary 
In patients with typical angina pectoris, inducable myocardial ischaemia and macroscopically normal 
coronaries (Cardiac Syndrome X, CSX) significantly elevated plasma level of terminal complement 
complex (TCC), the common end-product of complement activation, has been observed without 
subsequent activation of the classical or the alternative pathways. Therefore, our aim was to clarify 
the role of the ficolin-lectin pathway in CSX. Eighteen CSX patients, 37 stable angina patients with 
significant coronary stenosis (CHD) and 54 healthy volunteers (HC) were enrolled. Serum levels of 
ficolin-2, ficolin-3, ficolin-3/MASP-2 complex and ficolin-3 mediated TCC deposition (FCN3-TCC) were 
determined. Plasma level of TCC was significantly higher in CSX than in HC or in CHD groups (5.45 vs. 
1.30 vs. 2.04AU/ml, p<0.001). Serum levels of ficolin-2 and ficolin-3 were significantly lower in CSX 
compared to HC or to CHD groups (3.60 vs. 5.80 or 5.20µg/ml, p<0.05; 17.80 vs. 24.10 or 
26.80µg/ml, p<0.05). The ficolin-3/MASP-2 complex was significantly lower in CSX group compared 
to HC (92.90 vs. 144.90AU/ml, p=0.006). FCN3-TCC deposition was significantly lower in the CSX 
group compared to HC and to CHD (67.8% vs.143.3% or 159.7%, p<0.05). In the CSX group, 
significant correlation was found between TCC and FCN3-TCC level (r=0.507, p=0.032) and ficolin-
3/MASP-2 complex level and FCN3-TCC deposition (r=0.651, p=0.003). In conclusion, in patients with 
typical angina and myocardial ischemia despite macroscopically normal coronary arteries, low levels 
of several lectin-pathway parameters were observed, indicating complement activation and 
consumption. Complement activation through the ficolin-lectin pathway might play a role in the 
complex pathomechanism of CSX. 
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Introduction 
Our understanding of coronary syndromes has evolved in the last two decades from the paradigm of 
obstructive atherosclerosis of epicardial coronary arteries into the complex concept of anatomo-
functional abnormalities of coronary microcirculation. Under normal physiological conditions, the 
coronary microcirculation regulates myocardial perfusion in response to increased demand by 
endothelial-dependent and -independent mechanisms [1].  
Patients with typical angina pectoris and inducable myocardial ischaemia, but with 
macroscopically healthy coronaries has became commonly known as “Cardiac Syndrome X” (CSX, 
with incidence of 19 % in men and up to 48 % in women) [2, 3]. As an underlying pathomechanism, 
microvascular angina characterized by reduced coronary microvascular dilatory responses and 
increased coronary resistance has been suggested and consistently found in CSX patients [4]. In 
stable angina patients with proven myocardial ischemia and normal coronary arteries, significantly 
increased risks of future major adverse cardiac events and all-cause mortality was found compared 
to a normal population without ischemic heart disease, even after adjusting for traditional cardiac 
risk factors [3, 4]. Altough obvious explanation - namely endothelial dysfunction and other 
microvascular abnormalities in both coronary and peripheral arteries - has been suggested a decade 
ago, the complex pathomechanism has remained undetermined [5-8]. Taken together, stable angina 
patients with normal coronary arteries should be recognized as a unique clinical entity [9].  
Data about the role of complement system in angina patients with macroscopically normal 
coronary arteries are lacking.  As previously published [10], the level of terminal soluble C5b-9 
complex (TCC) was increased in plasma of this patient group compared to those with 
angiographically proven coronary atherosclerosis. In these patients, despite the lacking 
morphologically evident atherosclerotic lesions, complement system activation seems to be present.  
The complement system can be activated via three different routes, namely by the classical, 
the alternative, or the lectin pathways [11, 12]. The lectin pathway is triggered by the binding of 
mannose binding lectin (MBL) or ficolins to special carbohydrate structures on the surface of 
microorganisms, apoptotic cells or altered-self structures [13]. In humans, five initiation molecules of 
the lectin pathway have been described: MBL, the recently recognized ficolin-1 (M-ficolin), ficolin-2 
(L-ficolin), ficolin-3 (H-ficolin or Hakata antigen) and lately also collectin-11 [14-16]. While ficolin-1 
can be predominantly found intracellularly in leukocytes, ficolin–2 and ficolin–3 can be found mainly 
in serum [17]. MBL and ficolins in serum are complexed with MBL/ficolin-associated serine proteases 
(MASPs – ie, MASP-1, MASP-2, or MASP-3) and their truncated proteins (sMAP and MAP-1) [16, 18, 
19]. The initiation of the lectin pathway finally results in the formation of terminal pathway 
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activation complex (TCC or C5b-9), similarly to the previously mentioned classical, or alternative 
pathways. Importantly, MASPs can activate C4 and C2 leading to the generation of C3-convertase 
(C4b2b) of the complement classical and lectin pathways [13, 19].  
As we published previously [10], the high C1rC1sC1-INH level (observed in patients with 
significant coronary atherosclerosis) was an independent biomarker of ischaemic heart disease. In 
this study, the level of TCC was increased in patients with macroscopically healthy coronary arteries 
compared to those with angiographically proven coronary atherosclerosis. Since no parallel 
activation of the classical, or the alternative complement pathway was observed in this study, our 
findings indicated the potential involvement of the lectin pathway in the CSX patient population. 
Based on these results, our aim was to clarify the role of lectin pathway activation and ficolins in the 
CSX patient cohort. 
 
Materials and Methods 
Patient population 
In this case-control study we enrolled 55 patients scheduled for elective coronary angiography at our 
institution with diagnosis of stable angina pectoris. In each patient, non-invasive tests (exercise 
stress test, or myocardial perfusion scan) were performed before coronary angiography and were 
positive for inducible myocardial ischemia. The coronary angiography showed macroscopically 
normal coronary arteries, despite the history of typical angina and positive ischemia provocation 
non- invasive tests in 18 patients (CSX group). In 37 patients angiography indicated significant 
coronary artery stenosis (coronary heart disease: CHD group). These patients were referred to 
percutaneous coronary intervention, or to coronary artery bypass graft (CABG) surgery or were 
advised for conservative therapy. The cohort of stable angina patients was examined in a previous 
study, determining classical and alternative pathways of complement activation [10]. 54 healthy 
volunteers served as control (HC group).  
 
Blood samples 
In each patient, 8 ml of venous blood was drawn from the cubital vein into serum-separating tubes 
before coronary angiography. Peripheral blood samples were drawn from healthy subjects similarly. 
The serum was separated by centrifugation at 3000 rpm for 10 minutes at room temperature. The 
samples were immediately frozen at -80 ºC in aliquots, and were thawed only before the 
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measurement of lectin pathway parameters. Patient exclusion criteria were as follows: acute 
coronary syndrome, cardiogenic shock, history of severe renal or hepatic disease, hematological 
disorders, acute or chronic inflammatory disease and malignancy. The study protocol was approved 
by both the institutional review board of Semmelweis University of Budapest and the Hungarian 
Defence Forces Medical Centre. Informed consent was obtained in accordance with the Declaration 
of Helsinki. 
 
Measurement of the lectin pathway parameters  
The concentrations of ficolin-2 [20], ficolin-3 [21], the ficolin-3/MASP-2 complex [22], MAP-1 [23] 
and sC5b-9 (TCC) [10] were determined by previously described standard sandwich ELISA 
techniques, using monoclonal antibodies specific for each molecule. Biotinylated antibodies were 
added to the second layer, and streptavidin/HRP complexes were used for detection. All samples 
were tested in duplicate against a standard serum pool with known content of each analyte. Ficolin-
3-mediated terminal complement complex deposition (FCN3-TCC) was measured as described 
previously by Hein et al. [24]. In brief, acetylated bovine serum albumin (acBSA) was immobilized in 
Maxisorb ELISA plates and used as a ficolin-3 ligand. In order to block any interference from the 
classical pathway or the alternative pathway [25], full serum samples were pre-incubated with 
sodium polyanethole sulfonate (SPS). Serum samples were diluted 1:25 in barbital buffer containing 
0.05% Tween-20 (VBS-T), and incubated on the plate for 45 minutes at 37 °C. Thereafter, mouse-
anti-human TCC was applied for 2 hours at room temperature and then, rabbit-anti-mouse-HRP was 
added to the wells as secondary antibody, for 1 hour at 37 °C. Finally, the plates were developed 
using OPD substrate and the optical density was determined at 490/630 nm by ELISA reader 
(BioTek).  
 
Statistical analysis 
The statistical calculations were performed with Prism for Windows v5.02 (GraphPad Software Inc., 
San Diego, CA, www.graphpad.com), and SPSS v13.0 (SPSS Inc., Chicago, IL). Since most of the 
variables were non-Gaussian, non-parametric tests were applied. Mann–Whitney's U-test was used 
to compare two independent groups. Spearman rank correlation analysis was performed to analyze 
correlation between continuous variables. All the statistical analyses were two-tailed, and p<0.05 
was considered to represent a significant difference. 
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Results 
Demographic data 
Demographic data of the CSX and CHD populations are presented in Table 1. The 54 healthy 
volunteers (21 men and 33 women, median age: 33 years, 25th–75th percentiles: 21–58 years) did 
not have any known disease. Within the healthy control group, age and BMI (p<0.0001 for both 
comparisons) were significantly lower, compared to CSX and CHD groups, respectively. 
Both patient groups had increased presence of conventional cardiovascular risk factors, such 
as hypertension, type-2 diabetes mellitus, hyperlipidaemia, obesitas, previous cardiovascular event 
and tobacco use. The majority of the patients received antiplatelet therapy, ACE - inhibitor, beta- 
blocker, statin, or nitrate. No significant difference was found regarding medical therapy upon 
admission between patients groups (Table 1). Compared to CSX patients, significantly higher 
incidence of previous myocardial infarction (p=0.003, Fisher’s exact test) and percutaneous coronary 
intervention (p=0.003, Fisher’s exact test) was observed in the CHD group. Interestingly, there were 
no significant differences in body mass index, both groups were in the “overweight” category. The 
HDL-cholesterol level was significantly higher in CSX patients, compared to CHD patients (p=0.013, 
Mann–Whitney's U-test).   
When comparing laboratory parameters, we found no significant differences in kidney or 
liver function parameters between the patient groups.  
 
Serum and plasma levels of lectin pathway components  
The plasma level of TCC, the common end product of the complement activation pathways, was 
significantly higher in the CSX group compared to CHD and to HC (5.45 AU/ml vs. 2.04 AU/ml, 
p=0.0001; 5.45 AU/ml vs. 1.30, p<0.0001) (Table 2). These data represent a subgroup analysis of our 
previously published results [10]. 
The serum levels of ficolin-2 were significantly lower in CSX group compared to HC (3.60 
µg/ml vs. 5.80 µg/ml, p=0.005) and also lower compared to CHD group (3.60 µg/ml vs. 5.20 µg/ml, 
p= 0.052). Similarly, the serum levels of ficolin-3 were significantly lower in CSX group compared to 
HC (17.80 µg/ml vs. 24.10 µg/ml, p= 0.035) and to CHD (17.80 µg/ml vs. 26.80 µg/ml, p=0.016), as 
well (Table 2). 
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The ficolin-3/MASP-2 complex was significantly lower in CSX group compared to HC (92.90 
AU/ml vs. 144.90 AU/ml, p=0.006). Interestingly, the ficolin-3/MASP-2 complex was also significantly 
lower in the CHD group compared to HC (87.0 AU/ml vs. 144.90 AU/ml, p=0.011). 
The FCN3-TCC deposition was significantly lower in the CSX group compared to HC (67.8 % 
vs. 143.3 %, p=0.008) and to CHD (67.8 % vs. 159.7 %, p= 0.037), as well. There were no significant 
differences in serum MAP-1 levels, however, the levels tended to be the lowest in the CSX group 
(CSX: 178.60 ng/ml, HC: 194.50 ng/ml, CHD: 212.40 ng/ml) (Table 2).   
 
Correlations between serum lectin pathway parameters in the CSX group  
We found significant correlation between TCC and FCN3-TCC in the CSX group (r=0.507, p=0.032) 
(Figure 1/A). Similarly, the ficolin-3/MASP-2 complex level and FCN3-TCC deposition correlated 
significantly (r=0.651, p=0.003) (Figure 1/B).  
 
Cardiovascular risk factors and serum lectin pathway components  
When analyzing the total patient cohort (n=55), significantly higher TCC level (5.04 AU/ml vs. 2.05 
AU/ml, p=0.0002) was observed in non-smoking individuals compared to smoking patients. Presence 
of hypertension or diabetes mellitus, similarly to age, body-mass index, kidney and liver function 
parameters and CRP were not associated with the measured lectin pathway parameters.  
Importantly, among cardiovascular risk factors, patients with hyperlipidemia had significantly 
different levels of lectin pathway products. Ficolin-2, ficolin-3, ficolin-3/MASP-2 complex and FCN3-
TCC deposition was significantly higher within hyperlipidaemic CHD patients (Table 3).  Remarkably, 
this phenomenon was not observed in the CSX group (Table 3).  
Further evaluating hyperlipidaemic patients, we analyzed the serum lectin pathway 
parameters in respect to serum cholesterol and triglyceride levels.  When Spearman rank test was 
performed, serum lectin pathway component levels showed no significant correlation with serum 
cholesterol values. In contrast, we found significant correlation with ficolin-2, ficolin-3, ficolin-
3/MASP-2 complex, FCN3-TCC deposition and MAP-1 levels and serum triglyceride levels in the CHD 
group (Table 4).  It’s important to note, that such correlations were absent in the CSX group.   
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Medical therapy and serum lectin pathway parameters 
Intake of acetylsalicylic acid, ACE-inhibitors, beta-blockers and lipid-lowering agents were not 
associated with the measured lectin pathway parameters (data not shown).  
Patients on chronic clopidogrel therapy had significantly higher ficolin-3/MASP-2 complex 
(121.67 AU/ml vs 73.50 AU/ml, p=0.015) and ficolin-3 (30.40 µg/ml vs. 16.60 µg/ml, p=0.006) levels 
in the CSX subgroup, when compared to patients without such therapy. Similar phenomenon was 
not observed in the CHD group.  
 
Discussion 
Cardiac syndrome X remains a major diagnostic and therapeutic challenge causing significant 
deterioration in patient’s functioning and quality of life. Although substantial data report 
microvascular and endothelial dysfunction within this patient group, the complex pathomechanism 
is still unclear. 
In the present study we have demonstrated consumption of multiple parameters along the 
ficolin-lectin pathway. We observed significantly lower serum levels of ficolin-2, ficolin-3, ficolin-
3/MASP-2 complex and FCN3-TCC deposition accompanied by significantly higher TCC level in CSX 
patients compared to healthy controls and to patients with angiographically proven coronary heart 
disease. Furthermore, we found significant correlations between TCC and FCN3-TCC deposition, 
ficolin-3/MASP-2 complex level and FCN3-TCC deposition.  
According to these results, in the group of CSX patients consumption and activation of the 
ficolin-lectin pathway is present, best marked by low levels of ficolin-2 and ficolin-3. We consider 
lower ficolin-3/MASP-2 complex levels as a consequence of the decreased level of the ficolin-3 
component. Measurement of the FCN3-TCC, where the serum is activated with a ficolin-3 specific 
activator agent and the induced TCC-formation is analyzed is indicative for the remaining activity of 
the pathway. Decreased ficolin-3 mediated TCC-deposition is therefore a sign of prior in vivo 
activation and consumption of the ficolin-lectin pathway. 
Lectin pathway activation appears to have a controversial role in the cardiovascular system. 
While several studies pointed to a beneficial effect of the lectin pathway activation resulting in anti-
atherosclerotic effect [26, 27], others showed adverse cardiovascular effects of high MBL plasma 
concentration [28]. MASPs were associated with cardiovascular risk factors including dyslipidemia, 
obesity, and hypertension in patients with stable coronary artery disease [29]. Furthermore, MASP-2 
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plasma level was lower in myocardial infarction and stroke patients compared to stable coronary 
artery disease [29]. In a magnetic resonance study, ficolin-2, MBL and MAP-1 were associated with 
left ventricle dilatation after myocardial infarction indicating a potential role for lectin pathway 
products in myocardial remodeling [30].  
 Although our results suggest changes in lectin pathway complement cascade in CSX patients, 
our data can not verify causality between the measured parameters and pathogenesis of CSX. There 
is a general agreement, that the main pathological feature in the majority of CSX patients is 
microvascular/endothelial dysfunction [31]. Dollard et al. demonstrated that C-reactive protein 
(CRP) remains significantly higher in CSX patients who remain symptomatic than in either healthy 
controls [32]. Furthermore, coronary endothelial dysfunction may be associated with an increased 
release of constricting factors and the production of pro-inflammatory cytokines, cell adhesion 
molecules and growth factors (i.e. intracellular cell adhesion molecule-1 and vascular cell adhesion 
molecule-1).  Inflammatory and proliferative changes in the vessel wall might cause arteriole 
hyperplasia and perivascular fibrosis leading to microvascular dysfunction [33, 34, 35].  
Several members of the complement system were found to be deposited in the 
microvascular system of diabetic patients  (glomeruli and glomerular capillaries [36], retinal vessels 
[37] and choriocapillaries [38]). Based on our findings, namely the significantly lower serum levels of 
the ficolin-2, the ficolin-3, the ficolin-3/MASP-2 complex, we hypothesize that lectin-pathway 
product deposition might also occur in the subendothelial matrix and contribute to microvascular 
dysfunction. Besides, these activated molecules might bind to pathological structures on the surface 
of endothelial cells. It was described, that ficolins recognizes acetyl-group containing substances 
including N-acetylglucoseamine [39, 40] and glucan [41]. Furthermore, in addition to sugars, they 
also could bind to substances such as elastin and DNA [18]. An intact endothelium is a fully 
biocompatible surface that is not recognized by the complement system. However, blood contact 
with a damaged endothelium will lead to a certain degree of activation of the complement system 
[42].  
The end product of the complement activation, composed of components C5b, C6, C7, C8 
and C9, called terminal complement complex C5b-9 (TCC), or “membrane attack complex” (MAC). 
TCC facilitates the killing of bacteria and other pathogens by altering the permeability of their 
membranes. TCC was initially considered to be involved mainly in cytolytic processes of either 
pathogenesis or host cells [11]. Endothelial cells represent a potential target of TCC, which exerts a 
number of non-cytolytic effects [43]. Hoffmeister et al. described elevated C5b-9 levels in stable 
angina patients compared to healthy individuals [44]. Furthermore, in patients with acute coronary 
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syndromes the C5b-9 levels were even higher [44]. Our data are in agreement with these 
observations; TCC levels were lowest in healthy controls and significantly elevated in the CHD group. 
Interestingly, TCC levels were the highest in CSX patients. Excess amount of this membrane-attack 
complex might have a direct cytolytic effect on endothelial cells, contributing to the well-
documented above described endothelial dysfunction in these patients. 
There are several potential triggers of microvascular dysfunction, including many of the 
conventional cardiac risk factors such as hypertension, dyslipidemia and smoking [45]. Triglyceride 
levels correlated significantly with all the lectin pathway components in CHD but not in CSX patients. 
One can speculate, that the well-known relationship between high serum lipid levels, lipid 
accumulation and atherosclerotic plaques is absent in these patients. 
Emerging evidence suggests that platelets may have an ability to interact with both the 
classical and alternative pathway of complement activation [46]. Our results indicate that medical 
therapy with the platelet ADP receptor inhibitor clopidogrel was associated with the lack of ficolin-
lectin pathway consumption in CSX patients. Clopidogrel have a pleiotropic, anti-inflammatory and 
immune response/modulating effect, and might influence the lectin pathway of the complement 
system as well. However, low number of individuals on chronic clopidogrel therapy in the CSX cohort 
was inadequate to further analyze the complex effect. 
MBL, similarly to ficolins is a pattern recognition molecule and is an upstream component of 
the lectin pathway complement cascade [11, 12]. High level of MBL was found in ST-elevation 
myocardial infarction patients with reduced left ventricular systolic function [47]. Elevated MBL level 
was shown to be a risk factor for future development of coronary heart disease in healthy men [28]. 
In contrast, in a large prospective study high MBL level was associated with decreased risk of 
myocardial infarction independently of other cardiovascular factors [48]. Furthermore, MBL 
deficiency- associated genotypes were linked to increased early incidence of myocardial infarction 
[49]. Taken together, the role of MBL in the development of cardiovascular disease and/or prognosis 
is controversial and data regarding angina patients with macroscopically normal coronaries are 
completely missing. In the future, determination of the MBL level might be relevant in Cardiac 
syndrome X patients. 
In summary, we demonstrate significantly lower serum levels of lectin-pathway parameters, 
namely ficolin-2, ficolin-3, ficolin-3/MASP-2 complex and FCN3-TCC deposition and significantly 
higher TCC levels in CSX patients compared to healthy controls or to angiographically proven 
coronary heart disease patients. Low levels of several lectin-pathway products might reflect 
upstream consumption and consequent, downstream terminal complement complex activation. As 
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we hypothesized, complement activation might contribute to the increased cardiovascular risk of 
CSX patients by promoting endothelial and microvascular dysfunction. The topic of complement 
system activation via the lectin pathway requires further evaluation in a larger patient cohort with 
cardiac syndrome X.  
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Table 1.  
Demographic data 
CHD
(n = 37) 
CSX 
(n = 18) 
HC 
(n = 54) 
Age, mean ± S.D., years 61.44 ± 8.69 61.08 ± 8.81 35.00 ± 11.25a 
Males/females, n (%) 32 (86.4)/5(13.6) 9 (50)/ 9 (50) 21 (39)/ 33 (61)c 
BMI, mean ± S.D., kg/m2 29.06 ± 5.61 28.56 ± 4.73 23.69 ± 4.60a 
Risk factors  
 
History of tobacco use, n (%) 28 (75.6) 8 (44.4) 6 (11.1)a 
Hypertension, n (%) 32 (86.4) 14 (77.7) 5 (9.26)a 
Diabetes mellitus, n (%) 17 (45.9) 3 (16.6) 0 (0)a 
Hyperlipidemia, n (%) 17 (45.9) 7 (38.8) 2 (3.70)a 
Previous AMI, n (%) 18 (48.6)b 0 (0) 0 (0) 
Previous PCI, n (%) 19 (51.3)b 0 (0) 0 (0) 
Previous CABG, n (%) 6 (16.2)b 0 (0) 0 (0) 
Medication on admission   
 
Aspirin, n (%) 26 (70.27) 9 (50) 2 (3.70)a 
Clopidogrel, n (%) 25 (67.6) 5 (27.7) 0 (0)a 
ACE inhibitors, n (%) 31 (83.7) 11 (29.7) 1 (1.85)a 
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Beta blockers, n (%) 34 (91.9) 15 (83.3) 1 (1.85)a 
Lipid-lowering agents, n (%) 32 (86.4) 9 (50) 0 (0)a 
Nitroglycerine/nitrates, n (%) 9 (24.3) 5 (27.7) 0 (0)a 
Laboratory parameters  
 
CK, mean ± S.D. (U/l) 136.94 ± 58.63 101.40 ± 44.40 n.m. 
LDH, mean ± S.D. (U/l) 335.23 ± 63.93 268.36 ± 139.51 n.m. 
Cholesterol, mean ± S.D. (mmol/l) 4.15 ± 1.03 4.66 ± 1.31 4.84 ± 0.88c 
HDL cholesterol, mean ± S.D. 
(mmol/l) 0.98 ± 0.20
b 1.29 ± 0.41 1.55 ± 0.59 
LDL cholesterol, mean± S.D. 
(mmol/l) 2.44 ± 0.90 2.53 ± 0.94 2.57 ± 0.96 
Triglycerides, mean ± S.D. 
(mmol/l) 1.58 ± 0.71 1.56 ± 0.72 0.95 ± 1.01
c 
GOT, mean ± S.D. (U/l) 25.75 ±11.29 31.18 ± 19.45d 20.00 ± 5.46 
Creatinine, mean ± S.D. (µmol/l) 74.87 ± 14.70 78.83 ± 21.23 67.00 ± 12.29c 
CN, mean ± S.D. (mmol/l) 5.66 ± 1.46 6.66 ± 2.42 4.40 ± 1.02a 
CRP, mean ± S.D. (mg/l) 3.16 ± 2.23 2.49 ± 2.83 n.m. 
Fructosamine, mean ± S.D. 
(µmol/l) 233.82 ± 41.96 236.88 ± 32.57 n.m. 
 
Table 1. Demographic parameters. The values in parentheses represent percentages. Values are 
means ± S.D or n (%). Abbreviations: S.D.: standard deviation, CHD: patients with coronary heart 
disease, CSX: patients with negative coronary angiography, HC: healthy control individuals, BMI: 
Body mass index, CK, creatine kinase; LDH, lactat-dehydrogenase; AST, aspartate aminotransferase; 
CN, carbamide; n.m., not measured. Fisher’s exact test for the categorical variables, Mann-Whitney 
test for the continuous variables. Individuals in HC group received ASA and statin for primary 
prevention of cardiovascular events.  
a: significant differences in HC group compared to CSX and CHD groups, p<0.01 respectively 
b: significant differences in CHD group compared to CSX and HC groups, p<0.05 respectively 
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c: significant differences between CHD vs. HC group, p<0.05 
d: significant differences between CSX vs. HC group, p<0.05 
 
Table 2. 
  CHD CSX HC p value 
TCC, AU/ml 2.04 
(1.54 – 2.46) 
5.45
(3.71 – 7.62)
1.30
(0.93 – 2.29) 
0.0001a 
<0.0001b 
Ficolin-2, µg/ml 5.20  
(3.50 – 7.70) 
3.60
(3.20 – 4.70)
5.80
(4.20 – 8.0)
0.052a 
0.005b 
Ficolin-3, µg/ml 26.80  
(18.30 – 37.10) 
17.80
(12.90 – 25.30)
24.10
(18.20 – 30.10) 
0.016a 
0.035b 
MAP-1, ng/ml 212.40  
(169.80 – 237.60) 
178.60
(123.40 – 253.60)
194.50
(149.60 – 279.50) 
NS 
Ficolin-3/MASP-2 
complex, AU/ml 
87.0 
 (54.90 – 188.60) 
92.90
(39.40 – 121.70)
144.90
(89.80 – 336.20) 
0.506a 
0.006b 
Ficolin-3 mediated 
TCC-deposition,%  
159.70  
(72.70 – 203.0) 
67.80
(27.80 – 129.0) 
143.30
(91.90 – 195.30) 
0.037a 
0.008b 
 
Table 2. Serum lectin pathway parameter levels within the patient groups (CHD and CSX) and 
healthy controls (HC). 
The values in parentheses represent 25th-75th percentile. Values are given as medians. Abbreviations: 
CHD: patients with coronary heart disease, CSX: cardiac syndrome X patients  
a: CHD vs. CSX, b: CSX vs. HC  
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Table 3.  
  CHD CSX 
HL +/HL - HL +/HL - 
C5b-9, AU/ml 2.05/2.03 5.80/5.10 
Ficolin-3 med. TCC-deposition, %  170.50/81.60 (0.003) 77.30/51.60 
Ficolin-3/MASP-2 complex, AU/ml 132.60/72.02 (0.013) 94.40/88.0 
Ficolin-2 µg/ml  6.90/4.60 (0.047) 3.50/3.60 
Ficolin-3 µg/ml  34.30/18.40 (0.0001) 19.0/16.70 
MAP-1 ng/ml  227.90/207.70 185.0/171.0 
 
Table 3. Serum lectin pathway component levels according to presence/absence of 
hyperlipidemia. 
The values in parentheses represent p value. Values are given as medians.  
Abbreviations: HL: hyperlipidaemia, CHD: patients with coronary heart disease, CSX: cardiac 
syndrome X patients 
 
Table 4.  
 
Correlation between serum 
triglyceride levels and: 
 
CHD CSX 
sC5b-9 R=0.086 / p=0.691 R=-0.414 / p=0.098 
Ficolin-3 med. TCC-deposition  R=0.424 / p=0.043 R=-0.098 / p=0.737 
Ficolin-3/MASP-2 complex R=0.426 / p=0.042 R=-0.143 / p=0.626 
Ficolin-2  R=0.528 / p=0.009 R=0.055 / p=0.851 
Ficolin-3  R=0.512 / p=0.012 R=-0.200 / p=0.493 
MAP-1  R=0.449 / p=0.031 R=0.402 / p=0.154 
 
Table 4. Correlation between serum lectin pathway parameter levels and serum triglyceride levels 
in different patients subgroups.  
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Values represent the result of Spearman rank correlation analysis. 
Abbreviations: CHD: patients with coronary heart disease, CSX: cardiac syndrome X patients 
 
Figure Legends 
Figure 1. Correlations between serum lectin pathway components in the CSX group. Figure 1/A: 
correlation between TCC and FCN3-TCC in the CSX group. Figure 1/B: correlation of ficolin-3/MASP-2 
complex level and FCN3-TCC deposition.  
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